2019
DOI: 10.1016/j.ejca.2019.04.006
|View full text |Cite
|
Sign up to set email alerts
|

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation

Abstract: HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des labor… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
36
1
3

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 37 publications
(44 citation statements)
references
References 23 publications
4
36
1
3
Order By: Relevance
“… 7 , 9 The safety profile was also similar to adverse events structure observed for standard dose nivolumab treatment with 93.3% of patients experiencing adverse events during 40 mg nivolumab therapy. 7 10 The analysis also revealed the prognostic factors influencing the PFS of patients during nivolumab treatment: the presence of B-symptoms at the moment of nivolumab initiation and early response to therapy which is also in agreement with data reported from other groups. 25 …”
Section: Discussionsupporting
confidence: 87%
See 1 more Smart Citation
“… 7 , 9 The safety profile was also similar to adverse events structure observed for standard dose nivolumab treatment with 93.3% of patients experiencing adverse events during 40 mg nivolumab therapy. 7 10 The analysis also revealed the prognostic factors influencing the PFS of patients during nivolumab treatment: the presence of B-symptoms at the moment of nivolumab initiation and early response to therapy which is also in agreement with data reported from other groups. 25 …”
Section: Discussionsupporting
confidence: 87%
“… 3 6 The overall survival rate observed in this trial is in a good agreement with the results of clinical trials assessing the efficacy of the standard dose nivolumab (1 year OS 90%–93% in different cohorts) and pembrolizumab (2 year OS 89.4%–92.5% in different cohorts) as well as a real-life experience. 7 10 The response and restaging in current trial were based on the LYRIC criteria. One of the main aims of the LYRIC criteria is the prevention of the premature discontinuation of the therapy in patients with unconventional tumor response patterns.…”
Section: Discussionmentioning
confidence: 99%
“…There are investigators that use both allo-HSCT and auto-HSCT to consolidate the ICIs effect [22,24]. At the same time, an impressively high 3-year OS rate (95%) after nivo in our study, even in patients with progression, questions the need for transplantation at all [28].…”
Section: Discussionmentioning
confidence: 67%
“…In addition to primary resistance, acquired resistance mechanisms of ICB remain to be elucidated. Even in patients with HL, most eventually experience disease progression during anti-PD1 therapy [ 186 ]. Targeting other T cell checkpoint molecules may be a potential approach to overcome acquired resistance.…”
Section: Discussionmentioning
confidence: 99%